Navigation Links
The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System

Key words: CXCR2 • GPCR • receptor binding assay • LEADseeker • SPA Imaging Beads


Chemo-attractant cytokines (chemokines) are low molecular weight, pro-inflammatory cytokines with potent leukocyte activation and/or chemotactic activity in vivo (1). Chemokines are classified into four families (CXC, CC, C, and CXC3) based on the number and sequential relationship of the first two of four conserved cysteine residues. They induce their biological effect by binding to chemokine receptors that belong to the superfamily of G protein-coupled seven-transmembrane domain receptors (2).

The CXC chemokines are pivotal mediators that activate or inhibit angiogenesis by interacting with cognate receptors expressed by endothelial cells (3). CXCR2 is a major chemokine receptor expressed in neutrophils and binds chemokines with a Glu-Leu-Arg (ELR) sequence in the amino terminus; IL-8, GRO-α, GRO-β, GRO-γ, NAP-2, ENA-78, and GCP-2 (4).

This application note describes a 384-well CXCR2 chemokine receptor-binding assay which has been developed using the LEADseeker™ Multimodality Imaging System.


Materials
Products used
LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) PS SPA RPNQ0260
Imaging Beads

[125I]GRO-a IM305


Other materials required
Human recombinant CXCR2 receptor membrane preparation (Euroscreen ES-145-M)

Human recombinant IL-8 (Sigma 123K0714)

Human recombinant GRO-α(Sigma G0657)

Costar™ solid white 384-well NBS™ coated assay plate (Corning 3652)

EDTA-free protease inhibitor cocktail tablets (Roche 1873580)

Buffer: 25-mM HEPES pH 7.4, 5-mM MgCl2, 1-mM CaCl2, 0.2% (w/v) BSA, protease inhibitors (one tablet per 50-ml buffer).
Note: that BSA and protease inhibitors were added freshly on the day of use.

GraphPad Prism™ software (GraphPad Software)


Protocol
1. Human recombinant CXCR2 receptor membrane preparation was used in conjunction with [125I]GRO-αligand and WGA PS SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 125-nM IL-8. The standard assay format was as follows

2. Reagents were added in the following order: Buffer or DMSO solution, unlabeled ligand (NSB wells), labeled ligand, premixed bead, and membrane. Total assay volume was 40 µl

3. Diluted membrane and bead were premixed at room temperature immediately prior to assay addition.

4. Wells contained 10 µl of 1.48-nM [125I]GRO-α(final concentration 0.37 nM) unless otherwise stated. Wells also contained 0.1 mg of beads and 1.2 µg of membrane, which were added together in a 20-µl volume.

5. NSB wells contained 10 µl of 0.5-µM IL-8 (final concentration 0.125 µM) in addition to the above.

6. For DMSO tolerance studies, DMSO was diluted in binding buffer to give final concentrations per well as shown in the results.

7. Plates were sealed and incubated in darkness for 8 h at room temperature (20–25 ºC) unless otherwise stated.

8. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 3 min with quasi-coincident averaging and 3 ×3 binning.


Results

Kd determination
Saturation binding was performed with dilutions of [125I]GRO-αto give a range of concentrations from 2.5 to 2000 pM in the wells. Figure 1 shows the saturation curve that was fitted using non-linear regression with the data analysis software package GraphPad Prism v4.0. A Kd value of 383 pM (95% confidence intervals 318 to 447 pM) was estimated directly from the curve and Bmax was determined at 6 pmol/mg of protein.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 2% (v/v) to 25% (v/v) in the wells. From the results shown in figure 2 it can be seen that the assay was tolerant to DMSO up to a final concentration of 12.5% (v/v)

IC50 determination
Competitive binding of 0.37-nM [125I]GRO-αwith unlabeled IL-8 and GRO-αwas assessed and the IC50 values calculated as shown in Figure 3. DMSO was included at an assay concentration of 2.5% (v/v). Final concentrations in the well for unlabeled GRO-αwere 0.03 to 440 nM, and for unlabeled IL-8, 0.03 to 500 nM.

The IC50 value for GRO-αwas determined to be 2 nM (95% confidence interval range 1.7 to 2.3 nM) and the Ki value was 1.02 nM (95% confidence intervals 0.87 to 1.19 nM). The IC50 value for IL-8 was 11 nM (95% confidence interval range 10 to 12 nM) and the Ki was 5.68 nM (95% confidence intervals 5.14 to 6.27 nM).

Time course
A time course was performed using standard reagent concentrations as detailed in the protocol and DMSO included at an assay concentration of 2.5% (v/v). Readings were taken over an increased incubation time of 18 h. The assay reached equilibrium after approximately 7 h and was stable for at least a further 5 h as demonstrated by the results shown in Figure 4.

Zanalysis
Finally, a Z′analysis was performed using 48 replicate values each for "total" and NSB wells, Z′was determined to be 0.83 (Fig 5), which confirmed the robustness of the assay (5).


Conclusions
The CXCR2 chemokine receptor-binding assay has been successfully miniaturized to a 384-well format using the LEADseeker Multimodality Imaging System and is suitable for adaptation to automated screening formats. The assay is tolerant to DMSO up to a concentration of 12.5% (v/v), robust; achieving a Z′value of 0.83, and has a stability window of at least 5 h.


References
1. Rossi, D. and Zlotnik, A. Annual Review Immunology 18, 217–242 (2000).

2. Premack, B. A. and Schall, T. J. Nature Medicine 2, 1174–1178 (1996).

3. Addison, C. L. et al. Journal of Immunology, 165, 5269–5277 (2000).

4. Clark-Lewis, I. et al. Journal Biological Chemistry 278 (1), 289–295 (2003).

5. Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).



back to top
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
2. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
3. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
4. The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System
5. The development of a serotonin 5-HT2C receptor-binding assay using the LEADseeker Multimodality Imaging System
6. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
7. LiquiChip Kits for bead-based cytokine and kinase assays
8. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
9. High-content screening of GPCR activation with MetaXpress, AcuityXpress and the Transfluor assay system
10. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
11. Principles of Curve Fitting for Multiplex Sandwich Immunoassays, Rev B
Post Your Comments:
(Date:9/19/2014)... 2014 Cereal grain scientists, quality ... gather October 5–8, 2014, for the AACC International ... Center in Providence, Rhode Island. The comprehensive scientific ... food scientists, chemists, microbiologists, nutritionists, and those interested ... management. To date, 1,000 attendees have registered for ...
(Date:9/19/2014)... 2014 , The first grants ... Paediatric Endocrinology (ESPE) Meeting  Investment supports innovative ... in the field of growth  , EMD ... Germany , today announced the first recipients of ... awards were announced during a Satellite Symposium organized by ...
(Date:9/18/2014)... BELLINGHAM, Washington, USA (PRWEB) September 18, 2014 ... of Representatives of a bill designed to stimulate development ... high-value jobs is being praised by leaders of ... The bill, the Revitalizing American Manufacturing and Innovation (RAMI) ... vote. The bill’s authors have said they are optimistic ...
(Date:9/18/2014)... 2014 About POCT ... a clinical laboratory. It helps in making fast ... and medication. POCT is gaining popularity due to ... such as diabetes, heart disease, and obesity. It ... standardized to minimize errors during the diagnosis of ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... generally seem to be cheerful, happy-go-lucky characters, so you ... on life. , In fact some dogs are ... of Sydney shows. , "This research is exciting ... dogs objectively and non-invasively. It offers researchers and dog ... how that changes," said Dr Melissa Starling, from the ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... fossil fuel air pollution in the United States by ... , This novel way to measure carbon dioxide produced ... atmospheric scientists better understand where pollution is located and ... fossil-fuel-emitted carbon dioxide will be important as countries throughout ...
... used to help steady buildings against earthquakes, according to ... loose, sandy soil into rock. , When a major ... with disastrous consequences for buildings sitting on them. Currently, ... bind loose grains together. But these epoxy chemicals may ...
... Friedreich's ataxia is one of those diseases few have heard ... individual -- usually a child or teenager -- it is ... arms and legs, vision impairment and slurred speech, but eventually ... to heart failure later in life. There is no cure ...
Cached Biology News:Scientists map air pollution using corn grown in US fields 2Moonlighting enzyme linked to neurodegenerative disease 2Moonlighting enzyme linked to neurodegenerative disease 3
... The SPD101B is a no-frills, basic SpeedVac ... Although economically priced, this unit still features ... a digitial display of time and heat. ... samples and accepts a wide variety of ...
... Jouan RC Maxi MB (for aqueous, other ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
Biology Products: